Featured Research

from universities, journals, and other organizations

Childhood Vaccination May Protect Adult Eyes

Date:
September 20, 2007
Source:
University of Illinois at Chicago
Summary:
Childhood vaccination for the rubella virus may have also almost entirely eliminated an inflammatory eye disease from the US-born population, according to a new study. Currently, children commonly receive two doses of the vaccine by the time they are six years old. As a result of the vaccination program, the majority of U.S. rubella cases now occur in foreign-born individuals.

Childhood vaccination for the rubella virus may have also almost entirely eliminated an inflammatory eye disease from the U.S.-born population, according to a study by researchers at the University of Illinois at Chicago.

Fuchs heterochromic iridocyclitis, or FHI, is a chronic inflammatory disease of the eye that causes cataract and glaucoma and can lead to blindness. There is no effective treatment.

"We don't know what causes FHI," says Dr. Debra Goldstein, associate professor of ophthalmology and visual sciences at UIC. "But we were seeing changes in the incidence of the disease and in the makeup of the patient population with the disease -- fewer American-born FHI patients, and those we did see were older."

Although not able to establish the cause of FHI, earlier studies had found antibodies for rubella in the eyes of patients with FHI, suggesting that the rubella virus might be involved. The UIC researchers looked for epidemiological evidence that might link childhood vaccination for rubella, commonly known as German measles, with the decrease in the incidence of FHI they had observed.

"We hypothesized that if there was a relationship between rubella and FHI, then the proportion of FHI cases we were seeing at UIC would decrease after the institution of the national rubella vaccination program and that an increasing percentage of the FHI cases would be in patients coming from countries without a vaccination program," Goldstein said.

Patients with FHI and two other types of inflammatory eye disease who were seen at UIC between 1985 and 2005 were grouped by the decade of their birth to determine whether the percentage with FHI decreased relative to the two other inflammatory eye diseases. The percentage of foreign-born versus U.S.-born patients with FHI and the two control groups was also compared.

For U.S.-born patients born before rubella vaccinations (1919-1958) the percentages of FHI and two other eye inflammatory diseases were about equal. But there was a 69 percent drop in FHI in patients born the following decade (1959-1968) and a further 40 percent drop in patients born from 1969 to 1978. Only one FHI patient born during the decade 1979-1988 was seen.

Over the same periods, the percentage of foreign-born patients with FHI increased compared with the controls.

Rubella vaccination was implemented in the United States in 1969. By 1977, an estimated 60 percent of children had been vaccinated, with an 80 percent decline in cases.

Currently, children commonly receive two doses of the vaccine by the time they are six years old. As a result of the vaccination program, the majority of U.S. rubella cases now occur in foreign-born individuals.

The vast majority of eye inflammatory diseases have no known cause, according to Goldstein. "Although this kind of study has its limitations, it's exciting to find convincing epidemiological support for earlier research implicating the rubella virus as a cause of FHI," she said.

The study is published in the September issue of the American Journal of Ophthalmology.

Other authors on the report are Dr. Andrea Birnbaum, Dr. Howard Tessler, Dr. Frederick Oh and Weihua Gao of UIC; Dr. Kara Shultz of St. Louis University; Dr. Phoebe Lin of the University of California, San Francisco; and Marilyn Farber.


Story Source:

The above story is based on materials provided by University of Illinois at Chicago. Note: Materials may be edited for content and length.


Cite This Page:

University of Illinois at Chicago. "Childhood Vaccination May Protect Adult Eyes." ScienceDaily. ScienceDaily, 20 September 2007. <www.sciencedaily.com/releases/2007/09/070919154810.htm>.
University of Illinois at Chicago. (2007, September 20). Childhood Vaccination May Protect Adult Eyes. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/09/070919154810.htm
University of Illinois at Chicago. "Childhood Vaccination May Protect Adult Eyes." ScienceDaily. www.sciencedaily.com/releases/2007/09/070919154810.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins